Method to trick cancer cells to self-destruct shows promise in mice

Nov 23, 2010
In the Laboratory for Gene Therapy and Cellular Engineering, W T. Godbey has developed a treatment that would cause cancer cells to kill themselves. (Photo by Guillermo Cabrera-Rojo)

(PhysOrg.com) -- Tulane University researcher W T. Godbey has developed a treatment for cancer using a method that causes cancer cells to self-destruct while sparing surrounding healthy cells.

While clinical trials with human patients are two to three years in the future, the treatment has been successful in animal models.

Tulane has received a patent for the treatment, whereby Godbey takes a gene from a cancer cell, extracts the current message from the gene and replaces it with a code that instructs the cell to kill itself.

"We sort of trick the cancer cell," says Godbey, an associate professor of chemical and biomolecular engineering. “When a cell expresses a gene it doesn't look at the message; if it recognizes the promoter it transcribes the message. Here the message is to express key proteins that cause self-destruction.”

Only have the specific protein that will bind to this promoter; normal healthy cells do not, says Godbey. Other gene delivery methods have been tried before, but because his method targets only COX-2 expressing there are no bystander effects that would result in damage to healthy tissue.

The targeted treatment developed in Godbey’s lab has been proven successful on several carcinomas. Most recently, the gene therapy treatment has been shown to have exceptional cancer-killing actions when tested on bladder cancer in mice. This is a cancer that is especially difficult to treat due to a protective layer around the bladder wall, Godbey says. The results are reported in a recent article, "Preclinical Evaluation of a Gene Therapy Treatment for Transitional Cell Carcinoma," published in the journal Gene Therapy.

Pre-clinical trials are currently in process in collaboration with researchers at the Tulane University School of Medicine.

Explore further: New type of targeted therapy shows promise in preclinical models of B-cell malignancy

add to favorites email to friend print save as pdf

Related Stories

Nanoparticles Deliver Gene Therapy, Killing Tumors

Mar 26, 2009

(PhysOrg.com) -- Given that cancer is ultimately a genetic disease, it has long been the hope of researchers to use gene therapy to attack tumors where they might be most susceptible. Those prospects have taken a significant ...

New treatment hope for prostate cancer

Feb 06, 2009

Scientists at Melbourne's Burnet Institute have developed a potential new treatment for patients with prostate cancer. An article, which described the invention, has recently been published in the prestigious international ...

RNAi shows promise in gene therapy, researcher says

Feb 19, 2007

Three years ago Mark Kay, MD, PhD, published the first results showing that a biological phenomenon called RNA interference could be an effective gene therapy technique. Since then he has used RNAi gene therapy to effectively ...

Recommended for you

The fine line between breast cancer and normal tissues

15 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

16 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

19 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

dirk_bruere
not rated yet Nov 23, 2010
"While clinical trials with human patients are two to three years in the future..."
So if you have cancer now and are unlikely to last that long, thank the lawyers and ethics committees.
frajo
1 / 5 (1) Nov 24, 2010
Interested persons can apply to take part in preclinical trials.
But we should not risk another thalidomide catastrophe.